Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-6.38% $3.52
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 424.45 mill |
EPS: | -1.760 |
P/E: | -2.00 |
Earnings Date: | Feb 26, 2024 |
SharesOutstanding: | 120.58 mill |
Avg Daily Volume: | 2.14 mill |
RATING 2024-04-17 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.00 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.34x |
Company: PE -2.00 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-1.195 (-133.96%) $-4.72 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 3.10 - 3.94 ( +/- 12.05%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Alleva Lawrence M | Buy | 3 996 | Stock Option (right to buy) |
2024-01-13 | Mandelia Ashish | Buy | 0 | |
2024-01-15 | Protopapas Anna | Buy | 17 708 | Common Stock |
2024-01-15 | Protopapas Anna | Buy | 21 250 | Common Stock |
2024-01-16 | Protopapas Anna | Sell | 29 399 | Common Stock |
INSIDER POWER |
---|
74.94 |
Last 98 transactions |
Buy: 4 017 838 | Sell: 585 969 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.52 (-6.38% ) |
Volume | 2.60 mill |
Avg. Vol. | 2.14 mill |
% of Avg. Vol | 121.73 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.15 | N/A | Active |
---|
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.